These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 37371547)

  • 1. Caffeine for Prevention of Alzheimer's Disease: Is the A
    Merighi S; Travagli A; Nigro M; Pasquini S; Cappello M; Contri C; Varani K; Vincenzi F; Borea PA; Gessi S
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A
    Merighi S; Borea PA; Varani K; Vincenzi F; Jacobson KA; Gessi S
    Curr Med Chem; 2022; 29(24):4138-4151. PubMed ID: 34844537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective Effect of Caffeine in Alzheimer's Disease.
    M Yelanchezian YM; Waldvogel HJ; Faull RLM; Kwakowsky A
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeine and coffee as therapeutics against Alzheimer's disease.
    Arendash GW; Cao C
    J Alzheimers Dis; 2010; 20 Suppl 1():S117-26. PubMed ID: 20182037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
    Chen JF; Chern Y
    Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.
    Carman AJ; Dacks PA; Lane RF; Shineman DW; Fillit HM
    J Nutr Health Aging; 2014 Apr; 18(4):383-92. PubMed ID: 24676319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine: A Potential Protective Agent Against Cognitive Decline in Alzheimer's Disease.
    Hussain A; Tabrez ES; Mavrych V; Bolgova O; Peela JR
    Crit Rev Eukaryot Gene Expr; 2018; 28(1):67-72. PubMed ID: 29773015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neuroprotective effects of caffeine in neurodegenerative diseases.
    Kolahdouzan M; Hamadeh MJ
    CNS Neurosci Ther; 2017 Apr; 23(4):272-290. PubMed ID: 28317317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiological Role and Medicinal Chemistry of A
    Merighi S; Borea PA; Varani K; Vincenzi F; Travagli A; Nigro M; Pasquini S; Suresh RR; Kim SW; Volkow ND; Jacobson KA; Gessi S
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review.
    Panza F; Solfrizzi V; Barulli MR; Bonfiglio C; Guerra V; Osella A; Seripa D; Sabbà C; Pilotto A; Logroscino G
    J Nutr Health Aging; 2015 Mar; 19(3):313-28. PubMed ID: 25732217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer's mice.
    Cao C; Wang L; Lin X; Mamcarz M; Zhang C; Bai G; Nong J; Sussman S; Arendash G
    J Alzheimers Dis; 2011; 25(2):323-35. PubMed ID: 21422521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimer's Disease.
    Zhou X; Zhang L
    Oxid Med Cell Longev; 2021; 2021():5568011. PubMed ID: 34447487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of Caffeine in Alzheimer's Disease-A Review of Experimental Studies.
    Londzin P; Zamora M; Kąkol B; Taborek A; Folwarczna J
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33562156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
    Rivera-Oliver M; Díaz-Ríos M
    Life Sci; 2014 Apr; 101(1-2):1-9. PubMed ID: 24530739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice.
    Dall'Igna OP; Fett P; Gomes MW; Souza DO; Cunha RA; Lara DR
    Exp Neurol; 2007 Jan; 203(1):241-5. PubMed ID: 17007839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and Structural Insight into Adenosine A
    Karati D; Mukherjee S; Roy S
    Mol Neurobiol; 2023 Oct; 60(10):5987-6000. PubMed ID: 37391647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual blockade of the A1 and A2A adenosine receptor prevents amyloid beta toxicity in neuroblastoma cells exposed to aluminum chloride.
    Giunta S; Andriolo V; Castorina A
    Int J Biochem Cell Biol; 2014 Sep; 54():122-36. PubMed ID: 25058312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Opportunities for Caffeine and A2A Receptor Antagonists in Retinal Diseases.
    Boia R; Ambrósio AF; Santiago AR
    Ophthalmic Res; 2016; 55(4):212-8. PubMed ID: 26959995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?
    Flaten V; Laurent C; Coelho JE; Sandau U; Batalha VL; Burnouf S; Hamdane M; Humez S; Boison D; Lopes LV; Buée L; Blum D
    Biochem Soc Trans; 2014 Apr; 42(2):587-92. PubMed ID: 24646282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.